Medical device maker Boston Scientific has been a shocking success this year for investors, as its stock has jumped more than 80% year-to-date. Those are gains any investor can appreciate, but Boston's success hasn't come alongside its results.
Boston posted a solid second quarter that impressed Wall Street, but the company's still working on turning around from a lackluster past few years. The company's first-half sales fell year-over-year this year, mainly due to interventional cardiology and cardiac rhythm management businesses that have struggled to grow.
But Boston's outlook isn't bleak. The company just scored a big approval from the Food and Drug Administration in its small but growing electrophysiology business, and this segment has shown strong performance recently. Is Boston Scientific back on the path to success? Fool contributor Dan Carroll tells you all about this company's fortunes -- and what you can expect going forward -- in the video below.
Boston Scientific has outright exploded for investors this year with some spectacular gain. Don't let the quick money fool you, however: The best and easiest way to reach your financial goals is buying and holding top stocks for the long term. The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.
The article Is This the Start of Boston Scientific's Bounce Back? originally appeared on Fool.com.Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.